Product Description
ERK1 (Extracellular signal-regulated kinase 1), also known as MAPK3 (mitogen-activated protein kinase 3), is a member of the serine/threonine protein kinase family that plays a pivotal role in the Ras-Raf-MEK-ERK signaling cascade regulating cell proliferation, differentiation, survival, and migration. ERK1 is activated by phosphorylation via MEK1/2 in response to extracellular stimuli such as growth factors (e.g., EGF, FGF, PDGF), cytokines, and mitogens, which bind to receptor tyrosine kinases or G protein-coupled receptors. Beyond its role in normal cellular physiology, dysregulation of ERK1 signaling—often through activating mutations in upstream components like KRAS or BRAF—is closely associated with tumorigenesis, cancer metastasis, drug resistance, inflammatory disorders, and developmental syndromes, making it a highly validated target for cancer therapy and drug discovery.
Screeningbio’s ERK1 Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying ERK1 kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: ERK1 catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the ERK1 kinase.
Data